• ALK-Abelló Q2 revenue rose 18% to DKK 1.8 billion, driven by tablets and anaphylaxis products.
• EBIT climbed 19% to DKK 445 million; EBIT margin held at 25%.
• H1 EBIT margin was 28%; free cash flow increased to DKK 889 million, net debt to EBITDA was negative 0.6.
• Tablet sales advanced 22% to DKK 1.01 billion; Anaphylaxis & other products grew 26% to DKK 267 million.
• 2026 revenue growth outlook lifted to 14%-16%; CEO Peter Halling cited paediatric roll-out momentum and neffy launches.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALK-Abelló A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200130OMX_____CNEWS_DA_GNW1001258449_da) on August 20, 2026, and is solely responsible for the information contained therein.